Cover Image
市场调查报告书

重度乾癣:全球临床实验检讨

Severe Psoriasis Global Clinical Trials Review, H2, 2014

出版商 GlobalData 商品编码 318808
出版日期 内容信息 英文 116 Pages
订单完成后即时交付
价格
本报告书已不再贩售
Back to Top
重度乾癣:全球临床实验检讨 Severe Psoriasis Global Clinical Trials Review, H2, 2014
出版日期: 2014年10月31日 内容信息: 英文 116 Pages

本报告已在2018年01月18日停止出版

简介

本报告提供重度乾癣的临床试验相关的基本数据和数据,提供您实验数量及受验者的募集情况,各阶段趋势,临床试验的主要制药企业及研究机关简介等信息。

简介

  • 重度乾癣
  • 本报告概要

各地区的临床实验情形

  • 各国临床实验数量和平均实验人数
    • 亚太地区主要5个国家的临床实验数量
    • 欧洲主要5个国家的临床实验数量
    • 北美主要国家的临床实验数量
    • 中东·非洲主要国家的临床实验数量
    • 中南美主要5个国家的临床实验数量

G7各国临床实验数量:免疫疾病治疗药临床实验上重度乾癣所占的比例

G7各国的各阶段临床实验数量

G7各国临床实验数量:各进展状况

E7各国临床实验数量:免疫疾病治疗药临床实验上重度乾癣所占的比例

E7各国的各阶段临床实验数量

E7各国临床实验数量:各进展状况

各阶段临床实验数量

  • 进行中的临床实验:各阶段

各进展状况临床实验数量

临床实验的目标达成情形

未完成的临床实验数量

一定期间所采用的实验对像

赞助商类别的临床实验数量

有潜力的赞助商

重度乾癣治疗药临床实验的主要参与企业

有潜力的药剂

临床实验简介

  • 主要企业临床实验概要
    • AbbVie Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • E. Merck KG
    • F. Hoffmann-La Roche Ltd.
    • Innovaderm Research Inc.
    • Celgene Corporation
  • 有代表性的研究机关·医院临床实验概要
    • Rutgers, The State University of New Jersey
    • Academic Medical Center
    • National Cancer Institute
    • University of California, San Francisco
    • Tufts Medical Center
    • Dresden University of Technology
    • University Hospitals of Leicester NHS Trust
    • Erasmus MC
    • Radboud University Nijmegen Medical Centre
    • Rockefeller University

5个有代表性的临床实验简介

附录

目录
Product Code: GDHC2408CTIDB

GlobalData's clinical trial report, "Severe Psoriasis Global Clinical Trials Review, H2, 2014" provides data on the Severe Psoriasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Severe Psoriasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Severe Psoriasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Severe Psoriasis
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Severe Psoriasis to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Severe Psoriasis to Immunology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Severe Psoriasis
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Severe Psoriasis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • E. Merck KG
      • Clinical Trial Overview of E. Merck KG
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Innovaderm Research Inc.
      • Clinical Trial Overview of Innovaderm Research Inc.
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
    • Clinical Trial Overview of Top Institutes / Government
      • Rutgers, The State University of New Jersey
      • Clinical Trial Overview of Rutgers, The State University of New Jersey
      • Academic Medical Center
      • Clinical Trial Overview of Academic Medical Center
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Tufts Medical Center
      • Clinical Trial Overview of Tufts Medical Center
      • Dresden University of Technology
      • Clinical Trial Overview of Dresden University of Technology
      • University Hospitals of Leicester NHS Trust
      • Clinical Trial Overview of University Hospitals of Leicester NHS Trust
      • Erasmus MC
      • Clinical Trial Overview of Erasmus MC
      • Radboud University Nijmegen Medical Centre
      • Clinical Trial Overview of Radboud University Nijmegen Medical Centre
      • Rockefeller University
      • Clinical Trial Overview of Rockefeller University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Severe Psoriasis Therapeutics, Global, Clinical Trials by Region, 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Severe Psoriasis to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Severe Psoriasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Severe Psoriasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Severe Psoriasis to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Severe Psoriasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Severe Psoriasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Severe Psoriasis Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Severe Psoriasis Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Severe Psoriasis Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Severe Psoriasis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Innovaderm Research Inc., 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rutgers, The State University of New Jersey, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tufts Medical Center, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dresden University of Technology, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospitals of Leicester NHS Trust, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University Nijmegen Medical Centre, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rockefeller University, 2014*

List of Figures

  • Severe Psoriasis Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Severe Psoriasis to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Severe Psoriasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Severe Psoriasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Severe Psoriasis to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Severe Psoriasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Severe Psoriasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Severe Psoriasis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Severe Psoriasis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Severe Psoriasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top